ClinicalTrials.gov
public full text
Public Domain
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease#1214312
- Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)#875182
- A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease#909814
- CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)#855928
- Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease#1170972
Record · ID 1338131
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive